Avita is largely a single product company... Show more
AVITA Medical's third-quarter 2026 report matters because it shows whether the wound-care company can convert its recent commercial stabilization into sustained, profitable growth. After a turbulent 2025 marked by reimbursement disruptions and a leadership reset, AVITA has spent 2026 rebuilding demand for its flagship RECELL platform while scaling newer products such as Cohealyx and PermeaDerm. Investors were watching closely to see whether the stronger second quarter was repeatable and whether the company remains on track toward its stated goal of cash-flow breakeven in the fourth quarter. The results provide a direct read on hospital adoption, gross-margin durability amid a shifting product mix, and the pace of cash burn, all of which shape confidence in the company's liquidity and path to profitability.
For the fiscal quarter ended September 30, 2026, AVITA Medical reported total revenue of approximately $26.1 million, up 53% from $17.1 million in the prior-year period and up 20% sequentially from $21.7 million in the second quarter. Revenue exceeded the consensus estimate of roughly $22.35 million, and first-nine-month revenue reached about $67.1 million.
Net loss improved to $6.2 million, or $0.20 per basic and diluted share, compared with a net loss of $13.2 million, or $0.46 per share, a year earlier. The reported loss per share of $0.20 was narrower than the $0.24 loss analysts expected. Management noted the quarter included approximately $2.1 million in non-cash expense tied to the revaluation of warrants as the share price rose.
Gross margin expanded to 84%, up 270 basis points (hundredths of a percentage point) year over year, while RECELL-specific gross margin reached 88.4%. Operating expenses were approximately $24.6 million, roughly flat versus the second quarter. Net cash use narrowed sharply to about $0.6 million, and the company ended the quarter with roughly $10.5 million in cash and marketable securities. AVITA also raised its full-year 2026 revenue guidance to a range of $92 million to $94 million, up from $86 million to $89 million.
Tickeron's AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors following earnings-driven movers like AVITA Medical, it offers a structured way to surface comparable setups and monitor shifting market conditions.
Sentiment around the stock has been strengthening into the report, with shares closing at $15.68 and up more than 100% over the prior three months and roughly 361% over the trailing 12 months. The third-quarter print reinforced that momentum: a revenue beat, a narrower-than-expected loss, a second consecutive guidance raise, and a sharp reduction in cash use all aligned with the market's growing confidence that AVITA is executing on its turnaround. In after-hours trading following the release, shares rose more than 10%, reflecting investors' favorable interpretation of the results and the reaffirmed path toward cash-flow breakeven. The improved liquidity position, supported by drawing the remaining $10 million under the Perceptive Advisors credit facility, also helped ease balance-sheet concerns that had weighed on the stock earlier in the cycle.
Following the third-quarter results, the primary focus shifts to whether AVITA can reach its stated goal of cash-flow breakeven in the fourth quarter of 2026. Management's raised full-year guidance of $92 million to $94 million implies continued sequential revenue growth, and the declining trend in quarterly cash use, from $9.9 million in the first quarter to roughly $0.6 million in the third, suggests the company is moving closer to that milestone.
Investors should monitor gross margin stability as product mix evolves. Because AVITA shares a portion of average sales price with partners for Cohealyx and PermeaDerm, blended margins tend to run below RECELL's higher standalone margin. Management indicated it expects RECELL gross margin to remain between 86% and 90%, and any meaningful deviation could signal pricing or cost pressures.
Reimbursement developments remain a key watch item. With Medicare Administrative Contractors (MACs), the regional contractors that process Medicare claims, now publishing payment rates, adoption of RECELL and its smaller-wound RECELL GO Mini product has normalized. Proposed changes to how the Centers for Medicare & Medicaid Services (CMS) handles claims nationally could further influence utilization and ordering patterns into 2027.
Finally, portfolio adoption matters. Continued growth in hospitals using multiple AVITA products, along with forthcoming clinical data for Cohealyx and PermeaDerm, could expand the company's revenue opportunity within existing accounts. The balance between growth investments, operating-expense discipline, and liquidity will likely determine how the market evaluates the next stage of the company's recovery.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
a company, which engages in the development and distribution of regenerative and respiratory medicine and treatments
Industry MedicalNursingServices